Immucare Diagnostics Profile
Key Indicators
- Authorised Capital ₹ 1.10 M
as on 05-07-2024
- Paid Up Capital ₹ 1.00 M
as on 05-07-2024
- Company Age 5 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -10.21%
(FY 2023)
- Profit -46.86%
(FY 2023)
- Ebitda -44.61%
(FY 2023)
- Net Worth 43.24%
(FY 2023)
- Total Assets 14.86%
(FY 2023)
About Immucare Diagnostics
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Suryaprakasam Ramprasad, Surajit Chakrabartty, and Balamaniamma Nair serve as directors at the Company.
- CIN/LLPIN
U85300KL2019PTC057597
- Company No.
057597
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Apr 2019
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Ernakulam, Kerala, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Immucare Diagnostics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surajit Chakrabartty  | Additional Director | 19-Feb-2024 | Current |
| Suryaprakasam Ramprasad | Additional Director | 23-Apr-2024 | Current |
| Balamaniamma Nair | Director | 11-Apr-2019 | Current |
Financial Performance and Corporate Structure Insights of Immucare Diagnostics.
Immucare Diagnostics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.21% decrease. The company also saw a substantial fall in profitability, with a 46.86% decrease in profit. The company's net worth Soared by an impressive increase of 43.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Immucare Diagnostics?
In 2023, Immucare Diagnostics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Trident Diagnostics & Healthcare Private LimitedActive 8 years 5 monthsSuryaprakasam Ramprasad and Surajit Chakrabartty are mutual person
Ekavidha Corporate Services Private LimitedActive 9 years 8 monthsSurajit Chakrabartty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immucare Diagnostics?
Unlock and access historical data on people associated with Immucare Diagnostics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immucare Diagnostics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immucare Diagnostics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
